| Nov 11 |
Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'
|
| Nov 11 |
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
|
| Nov 11 |
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
|
| Nov 11 |
AbbVie Stock Slides on Schizophrenia Drug Study Failure
|
| Nov 11 |
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
|
| Nov 11 |
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
|
| Nov 11 |
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
|
| Nov 7 |
Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly
|
| Nov 6 |
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
|
| Nov 5 |
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
|
